Ultragenyx Pharmaceutical Inc. Annual Operating Income (Loss) in USD from 2012 to 2023

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Ultragenyx Pharmaceutical Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2012 to 2023.
Ultragenyx Pharmaceutical Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$132M, a 9.04% increase year-over-year.
Ultragenyx Pharmaceutical Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$536M, a 9.62% increase year-over-year.
Ultragenyx Pharmaceutical Inc. annual Operating Income (Loss) for 2023 was -$569M, a 12.3% increase from 2022.
Ultragenyx Pharmaceutical Inc. annual Operating Income (Loss) for 2022 was -$649M, a 70% decline from 2021.
Ultragenyx Pharmaceutical Inc. annual Operating Income (Loss) for 2021 was -$382M, a 15.6% decline from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Annual (USD)

Operating Income (Loss), YoY Annual Growth (%)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
2023	-$569M	+$79.7M	+12.3%	Jan 1, 2023	Dec 31, 2023	10-K	2024-02-21
2022	-$649M	-$267M	-70%	Jan 1, 2022	Dec 31, 2022	10-K	2024-02-21
2021	-$382M	-$51.6M	-15.6%	Jan 1, 2021	Dec 31, 2021	10-K	2024-02-21
2020	-$330M	+$94.1M	+22.2%	Jan 1, 2020	Dec 31, 2020	10-K	2023-02-17
2019	-$424M	-$52.8M	-14.2%	Jan 1, 2019	Dec 31, 2019	10-K	2022-02-15
2018	-$371M	-$42.4M	-12.9%	Jan 1, 2018	Dec 31, 2018	10-K	2021-02-12
2017	-$329M	-$80.9M	-32.6%	Jan 1, 2017	Dec 31, 2017	10-K	2020-02-14
2016	-$248M	-$100M	-67.9%	Jan 1, 2016	Dec 31, 2016	10-K	2019-02-20
2015	-$148M	-$91M	-160%	Jan 1, 2015	Dec 31, 2015	10-K	2018-02-21
2014	-$56.8M	-$24.5M	-75.9%	Jan 1, 2014	Dec 31, 2014	10-K	2017-02-17
2013	-$32.3M	-$16.3M	-102%	Jan 1, 2013	Dec 31, 2013	10-K	2016-02-26
2012	-$16M			Jan 1, 2012	Dec 31, 2012	10-K	2015-03-27

* An asterisk sign (*) next to the value indicates that the value is likely invalid.